• Shamoon, Harry (PI)

Project: Research project

Project Details


The question remains as yet unresolved as to the exact nature of the
relationship between metabolic control and microvascular complications in
type I diabetes. This proposal is to participate in the Diabetes Control
and Complications Trial--Phase III. During this phase, 30 subjects with
IDDM will be randomized into conventional or intensive treatment regimens.
Over a minimum of five years these subjects will be evaluated for metabolic
control and microvascular cmplications (retinopathy, neuropathy and
nephropathy). The standard treatment group (control) will be followed at
three month intervals with the aim of therapy to maintain the subjects free
of symptoms of hypo- and hyperglycemia. Treatment for this group is
characterized as one to two injections of mixed insulin with capillary
blood testing. The intensively treated group (experimental) will be
followed at least monthly with the aim of achieving and maintaining
euglycemia for the entire study period. For those intensively treated,
multiple injections of insulin or continuous subcutaneous insulin infusion
combined with frequent capillary blood testing will be employed.
Microvascular complications will be assessed at entry, periodically
throughout the study and at the five year point. Treatment will be
instituted and the subjects will be followed on the Model Demonstration
Unit of the Diabetes Research and Training Center. A multidisciplinary
team comprised of pediatric and adult diabetologists, nurse clinical
specialists, nutritionists and psychologists constitute the primary health
providers. Our goal will be to sustain near normal levels of glycemia in
the experimental group in order to clarify the relationship between control
and complications.
Effective start/end date12/31/892/28/97


  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.